Full Text:
<257>
Summary: 
<117>
Suppl. Mater.: 
CLC number:
On-line Access: 2023-12-08
Received: 2023-04-10
Revision Accepted: 2023-09-05
Crosschecked: 2023-12-12
Cited: 0
Clicked: 362
Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review
| ||||||||||||||
Fangfang GENG, Meifang YANG, Xuan ZHANG, Hong ZHAO, De ZHOU, Jianhua HU. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review[J]. Journal of Zhejiang University Science B, 2023, 24(12): 1159-1164.
@article{title="Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review",
author="Fangfang GENG, Meifang YANG, Xuan ZHANG, Hong ZHAO, De ZHOU, Jianhua HU",
journal="Journal of Zhejiang University Science B",
volume="24",
number="12",
pages="1159-1164",
year="2023",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300232"
}
%0 Journal Article
%T Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review
%A Fangfang GENG
%A Meifang YANG
%A Xuan ZHANG
%A Hong ZHAO
%A De ZHOU
%A Jianhua HU
%J Journal of Zhejiang University SCIENCE B
%V 24
%N 12
%P 1159-1164
%@ 1673-1581
%D 2023
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300232
TY - JOUR
T1 - Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review
A1 - Fangfang GENG
A1 - Meifang YANG
A1 - Xuan ZHANG
A1 - Hong ZHAO
A1 - De ZHOU
A1 - Jianhua HU
J0 - Journal of Zhejiang University Science B
VL - 24
IS - 12
SP - 1159
EP - 1164
%@ 1673-1581
Y1 - 2023
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300232
Abstract: Cytomegalovirus (CMV) infection is currently prevalent in populations throughout the world, and 56%–94% of the global population is seropositive for CMV. CMV infection mainly affects immunocompromised hosts. In these cases, it can cause significant symptoms, tissue-invasive disease, and many sequelae including death (Dioverti and Razonable, 2016). The vast majority of healthy adults with CMV infection experience an asymptomatic course; when symptomatic, it manifests as a mononucleosis-like syndrome in approximately 10% of patients (Sridhar et al., 2018). The gastrointestinal tract and central nervous system appear to be the most frequent sites of severe CMV infection in immunocompetent individuals (Rafailidis et al., 2008). However, CMV infection is relatively rarely recorded in immunocompetent hosts.
[1]ChenYH, LeeCH, PeiSN, 2015. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma, 56(5):1528-1529.
[2]DasR, GuanP, SpragueL, et al., 2016. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 127(13):1666-1675.
[3]DiovertiMV, RazonableRR, 2016. Cytomegalovirus. Microbiol Spectr, 4:4.
[4]GaoZR, LingXY, ShiCY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.
[5]HarrisonC, KiladjianJJ, Al-AliHK, et al., 2012. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med, 366(9):787-798.
[6]HeK, XuSS, ShenLJ, et al., 2022. Ruxolitinib as adjunctive therapy for hemophagocytic lymphohistiocytosis after liver transplantation: a case report and literature review. J Clin Med, 11(21):6308.
[7]HeineA, HeldSA, DaeckeSN, et al., 2013. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122(7):1192-1202.
[8]KeenanC, NicholsKE, AlbeituniS, 2021. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol, 12:614704.
[9]MengGQ, WangJS, WangYN, et al., 2021. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment. Infect Dis Now, 51(3):311-313.
[10]Parampalli YajnanarayanaS, StübigT, CornezI, et al., 2015. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol, 169(6):824-833.
[11]RafailidisPI, MourtzoukouEG, VarbobitisIC, et al., 2008. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J, 5:47.
[12]RisitanoAM, Peffault de LatourR, 2020. Ruxolitinib for steroid-resistant acute GVHD. Blood, 135(20):1721-1722.
[13]SepulvedaFE, de Saint BasileG, 2017. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol, 49:20-26.
[14]ShenCH, HwangCE, ChenYY, et al., 2014. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol, 93(6):1075-1076.
[15]SridharS, ChungTWH, ChanJFW, et al., 2018. Emergence of cytomegalovirus mononucleosis syndrome among young adults in Hong Kong linked to falling seroprevalence: results of a 14-year seroepidemiological study. Open Forum Infect Dis, 5(10):ofy262.
[16]TongLX, JacksonJ, KerstetterJ, et al., 2014. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol, 70(3):e59-e60.
[17]VannucchiAM, 2015. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med, 372(17):1670-1671.
[18]WangX, DaiCY, YinYF, et al., 2021. Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(6):492-503.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>